C15orf39 Activators
C15orf39 activators encompass a range of compounds that influence various signaling pathways, which may indirectly lead to the activation of C15orf39. These compounds generally act through well-established signaling cascades and cellular processes, such as the MAPK/ERK pathway initiated by EGF or the PI3K/AKT pathway activated by insulin. The involvement of C15orf39 in these processes would likely be indirect, through the molecular interplay within the cell that leads to the activation of downstream effectors.
For example, the activation of PKA by agents that increase cAMP levels, such as Forskolin and Isoproterenol, could lead to the phosphorylation of various proteins within the cell, including CSince there are no specific chemical compounds that are known to directly enhance the functional activity of C15orf39, or well-characterized indirect activators, the following table is constructed based on logical analysis of potential interactions with pathways or processes that could be related to the function of C15orf39, given its location in the chromosomal region 15 open reading frame 39.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which is involved in numerous signaling cascades. PKC activation could enhance the activity of C15orf39 if it is a substrate of PKC or involved in PKC-regulated pathways. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels. Elevated calcium can activate calmodulin-dependent pathways, potentially interacting with C15orf39 to enhance its activity. | ||||||
Insulin | 11061-68-0 | sc-29062 sc-29062A sc-29062B | 100 mg 1 g 10 g | $156.00 $1248.00 $12508.00 | 82 | |
Insulin activates the PI3K/AKT pathway, which is involved in cell survival and growth. C15orf39 could be an indirect target of this pathway, with its activity being enhanced as part of the cellular response to insulin. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol is a beta-adrenergic agonist that increases cAMP levels. This can lead to activation of PKA, which could potentially phosphorylate and activate C15orf39 if it is part of cAMP-responsive pathways. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium inhibits GSK-3β, which is part of the Wnt signaling pathway. Inhibition of GSK-3β can lead to activation of downstream targets, potentially including C15orf39 if it is involved in this pathway. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
Dibutyryl cAMP is a cAMP analog that activates PKA. PKA can then phosphorylate target proteins, potentially leading to the activation of C15orf39 if it is a PKA substrate. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin is a JNK activator. JNK signaling can lead to the activation of transcription factors and other signaling proteins, potentially including C15orf39 if it is involved in the JNK signaling pathway. | ||||||